There shall be no administrative or judicial review of any of the following: (1) The determination of a unit , with respect to a drug or biological product, pursuant to section 1320f(c)(6) of this title . (2) The selection of drugs under section 1320f–1(b) of this title , the determination of negotiation-eligible drugs under section 1320f–1(d) of this title , and [1] the determination of qualifying single source drugs under section 1320f–1(e) of this title the [2] application of section 1320f–1(f) of this title ,. [3] (3) The determination of a maximum fair price under subsection (b) or (f) of section 1320f–3 of this title . (4) The determination of renegotiation-eligible drugs under section 1320f–3(f)(2) of this title and the selection of renegotiation-eligible drugs under section 1320f–3(f)(3) of this title . (Aug. 14, 1935, ch. 531, title XI, § 1198, as added and amended Pub. L. 117–169, title I , §§ 11001(a), 11002(a)(5), Aug. 16, 2022 , 136 Stat. 1851 , 1861.) [1] So in original. The word “and” probably should not appear. [2] So in original. Probably should be preceded by “, and”. [3] So in original. Editorial Notes Amendments 2022—Par. (2). Pub. L. 117–169, § 11002(a)(5) , which directed the amendment of subsec. (b)(2) of this section by inserting “the application of section 1320f–1(f) of this title ,” after “ section 1320f–1(e) of this title ”, was executed by making the insertion in par. (2) to reflect the probable intent of Congress .